Trial Profile
Lopinavir/Ritonavir or Efavirenz as First-line Antiretroviral Therapy in Brazil: a "Real Life" Study.
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Efavirenz (Primary) ; Lopinavir/ritonavir (Primary) ; Nucleoside reverse transcriptase inhibitors
- Indications HIV-1 infections
- Focus Therapeutic Use
- 22 Jan 2010 New trial record